Join us on Monday, December 2nd at 2 pm in the Innovation Theater. for an exclusive clinical presentation by Dr. Jennifer Young, Interventional Radiologist, as she showcases planned future clinical studies with the NeedleVue technology.
For media inquiries, to schedule a meeting to discuss research collaboration, and/or further information, please contact: Heike Seck (hseck@deepsight.com).
Ad Statistics
Times Displayed: 2637
Times Visited: 16 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
About DeepSight™ Technology:
DeepSight Technology aspires to revolutionize medical ultrasound with groundbreaking imaging and interventional solutions. Founded in 2019, DeepSight has developed proprietary sensor technology that aims to surpass the capabilities of conventional piezoelectric sensors used in ultrasound imaging. NeedleVue is not yet authorized by the U.S. Food and Drug Administration (FDA) and is not available for sale in the United States. The first planned application of the device is in abdominal ultrasound (for ultrasound-guided biopsies). For further information about the company, please visit www.deepsight.com.
Back to HCB News
